Referral MD

FEBRUARY 28, 2025

While medical science advances, too many clinics still rely on cumbersome paperwork. For too long, the administrative side of healthcare has lagged behind its clinical advancements. Once prescribed the medication, you can include questions about weight loss and side effects to assess progress and make necessary adjustments.

Healthcare 52

Healthcare Healthcare Patients Electronics 52

PM360

SEPTEMBER 28, 2022

For instance, 61% of ophthalmologists cite poor adherence with existing treatments as a challenge; services to help patients and caregivers manage their condition emerged as their top need during the treatment stage. While physicians’ top go-to for medical information is scientific journals, used by 71% of all U.S.

Physicians 109

Physicians Pharma Education Pharma reps 109

PM360

APRIL 22, 2024

Medical science Liaisons know that change is coming; How are they cashing in? Medical science liaisons (MSLs) within pharmaceutical companies deal in a special currency: scientific exchange and real-world insights gathering. positive, negative, neutral) defined according to the organization’s strategic objectives.

Medical 52

Medical Education Medical science Customer Relationship Management 52

Medgadget

FEBRUARY 17, 2023

.” An attractive proposition in a world in which technology has contributed significantly to the distancing of physicians from their patients, usually leading to negative side effects. More info can be found at the Biomed Israel website.

Physicians 80

Physicians Engineering Leads Side effects 80

Celeritas

OCTOBER 23, 2022

This means that during the Q&A session, you may face a myriad of intricate medical, functional, or operational questions. A Medical Science Liaison’s job is to build relationships, so distinguishing yourself in these ways is paramount. For a Medical Science Liaison, having medical knowledge is a given necessity.

Medical science 40

Medical science Medical Specialization Doctors 40

European Pharmaceutical Review

AUGUST 15, 2024

BTKis, oral drugs given as continuous monotherapy, have revolutionised the treatment of CLL, with the first generation BTKi ibrutinib receiving European Medicines Agency (EMA) approval in 2014; however, side-effects (such as cardiovascular toxicities 2 ) have limited its suitability. BioMedical Engineering Online. 2022; 21(1).

Safety 52

Safety Patients Medical Medicine 52